Index of Contributors

Agarwal, K. C. 188-203
Agarwal, R. P., 160-168
Aiyar, V. N., 78-86
Aultman, M., 264-278

Babu, Y. S., 311-312
Balis, M. E., 142-149
Barankiewicz, J., 26-33, 302-304
Barton, R. W., 305-307
Bell, R., 160-168
Berkvens, Th. M., 332-335
Bluestein, H., 315-318
Bosman, F. T., 324-327
Bugg, C. E., 311-312
Buttin, G., 308-310

Carrera, C. J., 34-41
Carson, D. A., 34-41
Carter, D. C., 311-312
Castellazzi, M., 308-310
Chechik, B. E., 169-179
Chen, S. F., 188-203, 311-312
Cohen, A., 26-33, 302-304, 315-318
Cohen, M. B., 180-187
Cohen, S. S., 204-214
Coleman, M. S., 54-65
Cook, W. J., 311-312
Cronstein, B. N., 291-301

Daddona, P. E., 238-244
Danton, M. J., 54-65
Dawicki, D. D., 188-203
Dekker, B. M. M., 332-335
Dong, M. K., 313-314
Duyvesteyn, M. G. C., 245-249, 332-335

Ealick, S. E., 311-312
Elford, H. L., 98-112

Fernandes, B., 169-179
Fox, I. H., 42-53

Gelfand, E. W., 26-33, 169-179
Gerrard, T. L., 264-278
Giblett, E. R., 1-8
Gilbertsen, R. B., 313-314
Glazer, R. I., 180-187, 319-320
Goddard, J. M., 245-249
Goldblum, R. M., 66-77
Greenhough, T. J., 311-312
Gruber, H., 315-318

Habash, J., 311-312
Helliwell, J. R., 311-312
Hershfield, M., 78-86, 129-137
Hirschhorn, R., 20-25, 291-301
Hoffbrand, A. V., 123-128
Hsiao, N., 113-122
Hurley, M. C., 42-53
Hutton, J. J., 227-237

Iizasa, T., 34-41
Ingolia, D. E., 336-340
Israels, L. G., 319-320

Johnston, J. B., 319-320

Kajander, O., 34-41
Kaplan, A. M., 264-278
Karnovsky, M. L., 250-255
Kellems, R. E., 336-340
Kelley, W. N., 238-244
Khan, P. M., 324-327, 332-335
Koller, C. A., 129-137
Kramer, S. B., 291-301
Kubota, M., 34-41
Kurtzberg, J. 78-86

Lillquist, A., 160-168
Lin, A. L., 98-112
Lum, C. T., 113-122

Magnuson, N. S., 87-97
Margalith, M., 321-323
Martin, D. W., Jr., 245-249
McCaffrey, R., 160-168
McIvor, R. S., 245-249
Mills, G. C., 66-77
Minkowski, M., 308-310
Mitchell, B. S., 129-137

Najarian, J. S., 113-122
Niswander, P. W., 279-290

Orkin, S. H., 238-244

Parks, R. E., Jr., 188-203, 311-312
Perryman, L. E., 87-97
Philippeaux, M-M., 250-255
Philips, A., 54-65
Pike, M. C., 256-263
Plunkett, W., 150-159
Prentice, H. G., 123-128
Proctor, S., 123-128

Redelman, D., 315-318
Rosenstein, E. D., 291-301
Rule, S. A., 311-312

Schiff, R., 78-86
Schmalstieg, E. C., 66-77
Schrader, W. P., 169-179

Seegmiller, J. E., 9-19
SenGupta, S., 169-179
Seto, S., 34-41
Shewach, D. S., 238-244
Sidi, Y., 129-137
Simonsen, C. C., 245-249
Smyth, J. F., 123-128
Snyderman, R., 256-263
Spiers, A. S. D., 138-141
Squire, C., 264-278
Stoeckler, J. D., 188-203, 311-312
Strawson, J., 264-278
Suh, E. J., 78-86
Sutherland, D. E. R., 113-122

Ten Kate, J., 324-327
Tritsch, G. L., ix, 279-290

Ullman, B., 328-331

Valerio, D., 245-249, 332-335
van der Eb, A. J., 245-249, 332-335
van der Voorn, L., 332-335
van Ormondt, H., 245-249, 332-335
Vielh, P., 308-310

Wasson, D. B., 34-41
Weissmann, G., 291-301
Wiginton, D. A., 227-237
Wijnen, J. T., 324-327
Williams, S. R., 245-249
Willis, E. H., 34-41
Wolberg, G., 215-226

Yeung, C-Y., 336-340

Zimmerman, T. P., 215-226

Subject Index

Acquired immunodeficiency syndrome (AIDS), 4
Acyclovir, 16, 22
ADA conversion protein, 144, 147
Adenine arabinoside, 36–37, 114, 144, 150, 206-209
Adenine
  9-(1-hydroxy-2-octyl), 215, 224
  erythro-9-(2-hydroxy-3-nonyl), 15, 57, 60, 78, 99, 105, 114, 150, 206, 215, 257, 264, 293, 305, 321
Adenosine, 1, 5-6, 10, 21-22, 34, 36, 76, 101, 107, 109
Adenosine
  3-deaza-, 211, 257, 264
  5′-*N*-ethylcarboxamido-, 292
  5′-*S*-isobutyl-, 211
  1-methyl-, 69, 71, 73, 76
  5′-methylthio-, 68, 71
  N^6-phenylisopropyl-, 292
Adenosine binding protein, 79-80, 324
Adenosine receptor, 20, 189, 223, 291, 298
S-Adenosylhomocysteine, 13-14, 16, 24, 67, 76, 78-79, 94, 98, 111, 129, 223, 264
S-Adenosylmethionine, 66-67, 76, 111, 129, 210
AIDS *see* Acquired immunodeficiency syndrome
Alanosine, 6
Alleles, of ADA, 2, 229
Allopurinol, 138, 272, 285, 288
AMP Deaminase, 59, 82, 88-90, 161, 281, 302, 309
cAMP, *see* Cyclic AMP
Antibodies to ADA, 61-62, 82, 228, 333
Aplastic anemia, 6
Arabinosyl adenine, *see* Adenine arabinoside
Arachidonic acid, 256, 258
ATP (and dATP), 5, 13-16, 21-22, 24, 27, 30-31, 37, 55, 57-58, 67, 81-82, 88, 98, 110, 131, 156, 206, 224, 302
Azathioprine, 119

Basophils, 292
B cells, 2, 4, 10, 15, 21-22, 36, 55, 87, 162
Bone marrow, 1, 2, 5, 16, 22-23, 57, 62, 80-81, 125, 180, 305, 319
Burkitt's lymphoma, 4

Carrier DNA, 6, 62, 82, 227, 332, 336
Cell division cycle, 27, 34, 100
Chlorodeoxyadenosine, 36-38
Cholera enterotoxin, 223
Chromatography
  affinity, 42, 43
  gel filtration, 46, 80, 146
  HPLC, 59, 130, 157, 217, 239, 313, 317, 319
  ion exchange, 42, 69
  thin-layer, 89, 259
Chromosome 6, 11
Chromosome 8, 4
Chromosome 14, 4
Chromosome 20, 2, 11, 81, 238
Chronic lymphocytic leukemia, 58
Coformycin, 15, 57, 60, 150, 180, 215
Cordycepin, 207, 209, 211
Corticosteroids, 40
Creatinine, 120, 124
Cyclic AMP, 14, 24, 98, 189, 195, 212, 217, 222, 279, 291
Cycloheximide, 105, 107, 110, 142
Cyclosporine, 121
Cytidine, 3-methyl, 69, 76
Cytidine deaminase, 205
Cytomegalovirus, 118, 121
Cytosine arabinoside, 36-37, 205

Deoxyadenosine, *see* Adenosine
Deoxycholate, 283
Deoxycoformycin, 6, 16, 36-38, 57-60, 78, 82, 84, 110, 114, 123, 129, 138, 150, 154, 174, 207, 215, 274, 295, 302, 305, 315, 337
Deoxycytidine kinase, 205
Digitonin, 283
Dipyridamole, 223, 297
cDNA, *see* Carrier DNA

EHNA *see* Adenine, erythro-9-(2-hydroxy-3-nonyl)
Electrophoresis, 2, 248, 321
  SDS polyacrylamide gel, 60, 145, 172, 229
Epstein-Barr (EB) virus, 228, 321, 328

Flow cytometry, 176
5-Fluorouracil, 204
Folate, 285, 288-289
Formycin, 16
Formyl-methionyl-leucyl-phenylalanine, 257, 291, 294

Gene amplification, 6
Germ-free, 69, 71, 73, 77
Glyceraldehyde-3-phosphate dehydrogenase, 38-39
Glycolysis, 39
Granulocyte, 11, 54, 60, 62, 84, 250, 319, 332
GTP, 5, 28, 31, 39
Guanine, 5-6
  arabinosyl-, 328
  1-methyl-, 69, 75, 76
  7-methyl-, 69, 71, 75
Guanosine, 5-6, 15, 29, 66, 313
  8-amino-, 313
  deoxy-, 328
  N^2, N^2-dimethyl-, 69
  N^2-methyl-, 69
  1-methyl-, 69

Hemolytic anemia, 6, 22, 83
Herpes virus, 206-207, 210
Histamine, 223, 256
HOA *see* Adenine, 9-(1-hydroxy-2-octyl)
Homocysteine, 13-14
Hybridoma cell lines, 62
Hydrogen peroxide, 267, 272
Hypoxanthine, 5, 12, 66, 76, 296

Inosine, 5, 10, 12-14, 16, 29, 66, 82, 162, 296, 302, 313
  1-methyl-, 69
  p-nitrobenzylthio-, 189, 221
Interferon, 211
Interleukin, 87
Ionizing radiation, 40
Isoproterenol, 223

Kinases, 11, 14, 34-37, 42, 58, 67, 79, 83, 88, 161, 197, 220, 253

Lesch-Nyhan disease, 13
Leukemia
  acute lymphoblastic, 123, 134, 140, 170
  chronic lymphocytic, 138, 155, 162, 186
  chronic myeloid, 123, 162
  hairy-cell, 138, 186, 319
Lymphocytes, 1, 10-11, 15, 293

Macrophages, 84, 250, 273, 332
Mast cells, 292
Maximum velocity, 13, 91
Metabolic selection, 62-63
Metabolism, 5, 27
Michaelis constant, 13, 48, 51, 91, 142, 162, 279
Mutant ADA, 60-61
Mycosis fungoides, 58, 124, 127, 140, 158, 186
Myelocytic leukemia, 6

NAD (and NADP), 38-40, 67, 279, 285
Northern blots, 234, 236, 242, 332
Nucleotidase, 10, 29, 34-36, 66, 90, 147, 162, 200, 250

Overproduction of ADA, 6

Phytohemagglutinin, 56, 180, 275, 293, 315
Prostaglandins, 223
Pseudouridine, 69
Pterin aldehyde, 289
Purine nucleoside phosphorylase, 3-4, 6, 10, 15-16, 20, 26, 30, 39, 66, 78, 87, 164, 200, 281, 311

Ribonucleotide diphosphate reductase, 34, 36, 40, 94, 98, 101

Sézary's syndrome, 140, 158
Southern blots, 247, 333
Spermatozoa motility, 215
Spermidine, 67
Spermine, 67
Splenectomy, 117
Superoxide anion, 251, 257, 260, 265, 271, 280, 291
Superoxide dismutase, 258, 281

T cells, 2, 4-6, 10, 16, 21-22, 26, 34, 36-37, 40, 55, 78, 84, 87, 117, 126, 130, 162, 267

TCNR (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), 16
Terminal deoxynucleotidyl transferase, 55, 124, 145, 163, 306
Tetrahydrouridine, 205
Theophylline, 224, 292
Therapy, 5, 123
Thymidine phosphorylase, 205
Thymidylate synthetase, 204
Thymineless death, 204
Thymus leukemia-associated antigen, 145
Transplantation, 1, 16, 113, 180
Tuftsin, 283

Uric acid, 12, 66, 162, 279
Uridine, 6
Uridine phosphorylase, 205

Waldenstrom's macroglobulinemia, 140

Xanthine oxidase, 12, 162, 272, 279

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 451
October 18, 1985

ADENOSINE DEAMINASE IN DISORDERS OF PURINE METABOLISM AND IN IMMUNE DEFICIENCY[a]

Editor and Conference Organizer

GEORGE L. TRITSCH

CONTENTS

Preface. *By* GEORGE L. TRITSCH xi

Part I. Relation of Purine Metabolism to Immune Deficiency

ADA and PNP Deficiencies: How It All Began. *By* ELOISE R. GIBLETT 1

Overview of Possible Relation of Defects in Purine Metabolism to Immune Deficiency. *By* J. EDWIN SEEGMILLER 9

Complete and Partial Adenosine Deaminase Deficiency: Relationship of Immune Function to Metabolite Concentrations, Enzyme Activity, and Effects of Therapy. *By* ROCHELLE HIRSCHHORN 20

Roles of Alternative Synthetic and Catabolic Purine Pathways in T Lymphocyte Differentiation. *By* AMOS COHEN, JERZY BARANKIEWICZ, and ERWIN W. GELFAND 26

Metabolic Basis for Immune Dysfunction in Adenosine Deaminase Deficiency. *By* DENNIS A. CARSON, TAIZO IIZASA, SHIRO SETO, CARLOS J. CARRERA, MASARU KUBOTA, ERIK H. WILLIS, DONALD B. WASSON, and OLAVI KAJANDER 34

Human Placental Nucleoside Kinase Activities. *By* MARY C. HURLEY and IRVING H. FOX 42

Adenosine Deaminase and Immune Dysfunction: Biochemical Correlates Defined by Molecular Analysis throughout a Disease Course. *By* MARY SUE COLEMAN, MARY JO DANTON, and ANNE PHILIPS 54

[a] The papers in this volume were presented at the Conference on Adenosine Deaminase in Disorders of Purine Metabolism and in Immune Deficiency, which was held by The New York Academy of Sciences on September 5-7, 1984 in New York City.

Urinary Purines and Nucleosides in Immune Deficiencies. *By* GORDON C. MILLS, FRANK C. SCHMALSTIEG, and RANDALL M. GOLDBLUM 66

Abnormalities in *S*-Adenosylhomocysteine Hydrolysis, ATP Catabolism, and Lymphoid Differentiation in Adenosine Deaminase Deficiency. *By* MICHAEL S. HERSHFIELD, JOANNE KURTZBERG, V. NAMBI AIYAR, EALL JOO SUH, and RICHARD SCHIFF 78

Metabolic Investigations of Horses with Severe Combined Immunodeficiency. *By* NANCY S. MAGNUSON and LANCE E. PERRYMAN 87

Adenosine Deaminase Impairment and Ribonucleotide Reductase in Human Cells. *By* HOWARD L. ELFORD and ALAN L. LIN 98

Part II. Clinical Observations

Relevance of Adenosine Deaminase to Organ Transplantation. *By* CALIANN T. LUM, DAVID E. R. SUTHERLAND, NINA HSIAO, and JOHN S. NAJARIAN 113

Deoxycoformycin in the Treatment of Leukemias and Lymphomas. *By* JOHN F. SMYTH, H. GRANT PRENTICE, STEPHEN PROCTOR, and A. VICTOR HOFFBRAND 123

Biochemical Consequences of Adenosine Deaminase Inhibition *in Vivo:* Differential Effects in Acute and Chronic T Cell Leukemia. *By* BEVERLY S. MITCHELL, YECHEZKEL SIDI, MICHAEL HERSHFIELD, and CHARLES A. KOLLER 129

The Activity of Deoxycoformycin (Pentostatin) in Refractory Leukemias and Lymphomas. *By* ALEXANDER S. D. SPIERS 138

Part III. ADA Activity As Related to Neoplasia

Adenosine Deaminase and Malignant Cells. *By* M. EARL BALIS 142

Inhibition of Adenosine Deaminase to Increase the Antitumor Activity of Adenine Nucleoside Analogues. *By* WILLIAM PLUNKETT 150

Purine Metabolism in Leukemia. *By* RAM P. AGARWAL, RICHARD BELL, ANNE LILLQUIST, and RONALD MCCAFFREY 160

Association of Adenosine Deaminase with Differentiation of Normal and Leukemic T and B Lymphocytes. *By* B. E. CHECHIK, W. P. SCHRADER, B. FERNANDES, S. SENGUPTA, and E. W. GELFAND 169

Inhibition of Interleukin-2 Messenger RNA in Mouse Lymphocytes by 2′-Deoxycoformycin and Adenosine Metabolites. *By* MARVIN B. COHEN and ROBERT I. GLAZER 180

Part IV. Biological Studies

Role of Nucleoside Transport in Drug Action: The Adenosine Deaminase Inhibitor, Deoxycoformycin, and the Antiplatelet Drugs, Dipyridamole and Dilazep. *By* ROBERT E. PARKS, JR., DOLORETTA D. DAWICKI, KAILASH C. AGARWAL, SHIH-FONG CHEN, and JOHANNA D. STOECKLER 188

Inhibitors of Adenosine Deaminase and the Development of Antiviral Agents. *By* SEYMOUR S. COHEN 204

Effects of Adenosine Deaminase Inhibitors on Lymphocyte-mediated Cytolysis. *By* GERALD WOLBERG and THOMAS P. ZIMMERMAN 215

Molecular Biology of the Adenosine Deaminase Gene and Messenger RNA. *By* JOHN J. HUTTON and DAN A. WIGINTON 227

cDNA and Amino Acid Sequence of Human Adenosine Deaminase. *By* PETER E. DADDONA, STUART H. ORKIN, DONNA S. SHEWACH, and WILLIAM N. KELLEY 238

Mammalian Expression of Cloned cDNA Sequences Encoding Human Purine Nucleoside Phosphorylase and Adenosine Deaminase. *By* R. SCOTT MCIVOR, DINKO VALERIO, STEVEN R. WILLIAMS, JUDY M. GODDARD, CHRISTIAN C. SIMONSEN, MARJA G. C. DUYVESTEYN, HANS VAN ORMONDT, ALEX J. VAN DER EB, and DAVID W. MARTIN, JR. 245

Part V. Control of Purine Metabolism in Phagocytosis

Ectoenzyme Action on Purine Nucleotides in Macrophages and Subsequent Reactions. *By* MANFRED L. KARNOVSKY and MARIE-MARTHE PHILIPPEAUX 250

Regulation of Mononuclear Leukocyte Function by Transmethylation Reactions. *By* MARILYN C. PIKE and RALPH SNYDERMAN 256

Role of Adenosine Deaminase in Human Monocyte Differentiation and Tumor Cell Cytotoxicity. *By* ALAN M. KAPLAN, THERESA L. GERRARD, JOAN STRAWSON, COLES SQUIRE, and MARSA AULTMAN 264

Purine Catabolism as a Source of Superoxide in Macrophages. *By* GEORGE L. TRITSCH and PAUL W. NISWANDER 279

Adenosine Modulates the Generation of Superoxide Anion by Stimulated Human Neutrophils via Interaction with a Specific Cell Surface Receptor. *By* BRUCE N. CRONSTEIN, SARA B. KRAMER, ELLIOT D. ROSENSTEIN, GERALD WEISSMANN, and ROCHELLE HIRSCHHORN 291

Poster Papers

Impairment of dATP but Not ATP Catabolism in Adenosine Deaminase Deficiency. *By* JERZY BARANKIEWICZ and AMOS COHEN 302

Thymocyte Differentiation and ADA Inhibition. *By* RANDALL W. BARTON 305

ADA Activity Levels in IL-2-dependent Cultured Murine Cytotoxic T Lymphocytes. *By* M. CASTELLAZZI, M. MINKOWSKI, P. VIELH, and G. BUTTIN 308

Three-Dimensional Structure of Human Erythrocytic Purine Nucleoside Phosphorylase. *By* S. E. EALICK, T. J. GREENHOUGH, Y. S. BABU, D. C. CARTER, W. J. COOK, C. E. BUGG, S. A. RULE, J. HABASH, J. R. HELLIWELL, J. D. STOECKLER, S. F. CHEN, and R. E. PARKS, JR. 311

Effects of 8-Aminoguanosine, an Inhibitor of Purine Nucleoside Phosphorylase, on Plasma Nucleosides in Wistar Rats. *By* RICHARD B. GILBERTSEN and MI K. DONG 313

Levels of dATP in ADA-inhibited Human Peripheral Blood B and T Lymphocytes Cultured in Deoxyadenosine. *By* H. GRUBER, A. COHEN, D. REDELMAN, and H. BLUESTEIN 315

The Treatment of Hairy-Cell Leukemia with 2'-Deoxycoformycin. *By* JAMES B. JOHNSTON, LYONEL G. ISRAELS, and ROBERT I. GLAZER 319

Adenosine Deaminase Activity in Human Lymphoma Daudi Cells, Producers and Nonproducers of Herpes Simplex Type 1 Virus. *By* MIRIAM MARGALITH 321

Adenosine Deaminase Complexing Protein in Transformed Cells and Colon Cancer. *By* JOOP TEN KATE, JUUL T. WIJNEN, FRED T. BOSMAN, and P. MEERA KHAN 324

Arabinosylguanine Toxicity in Syngeneic Cultured Human T and B Lymphoblasts. *By* BUDDY ULLMAN 328

The Human Gene for Adenosine Deaminase: Its Structural Organization and Expression in Mouse Cells. *By* D. VALERIO, TH. M. BERKVENS, M. G. C. DUYVESTEYN, L. VAN DER VOORN, B. M. M. DEKKER, H. VAN ORMONDT, P. MEERA KHAN, and A. J. VAN DER EB 332

Rapid Identification of Functional Murine Adenosine Deaminase cDNA Clones by Genetic Complementation in Bacteria. *By* CHO-YAU YEUNG, DIANE E. INGOLIA, and RODNEY E. KELLEMS 336

Index of Contributors 341

Subject Index 343